Medical information Clinical review pending

Genetic Testing

Kras Nras Mutation Analysis Panel Test

The KRAS/NRAS Mutation Analysis Panel Test identifies specific genetic mutations in KRAS and NRAS genes, crucial for guiding cancer treatment decisions, particularly for colorectal, lung, and melanoma cancers.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question

Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample: A formalin-fixed paraffin-embedded (FFPE) tissue block containing at least 10% tumor tissue is required. The sample should be shipped at room temperature.
Results: Reports are typically available the following Monday if the sample is submitted by Tuesday at 11 am. Confirm with the laboratory before booking.
Preparation: No specific patient preparation is required. Ensure the FFPE tissue block is properly labeled and accompanied by a completed NGS Test Requisition Form (Form 40). Confirm with the laboratory before booking.

Test priceKSh 30,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Kras Nras Mutation Analysis Panel Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

Insurer or scheme name & policy / member number
A clinician's request / prescription for the test
Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

Full name *

Mobile number *

+254

Insurer or scheme

Policy / member number (optional)

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

✓Patients diagnosed with colorectal cancer.
✓Patients diagnosed with lung cancer.
✓Patients diagnosed with melanoma.
✓Patients where targeted therapy selection is needed.
✓Patients with cancer requiring personalized treatment planning.

In plain language

What this test helps you understand

This test helps oncologists determine if a patient's cancer is likely to respond to specific targeted therapies based on the presence of KRAS or NRAS mutations. It aids in selecting the most effective treatment plan and improving patient prognosis.

The KRAS/NRAS Mutation Analysis Panel Test is a vital diagnostic tool used in oncology to detect mutations within the KRAS and NRAS genes. These genes regulate cell growth, and mutations in them are frequently found in various cancers, including colorectal, lung, and melanoma. Identifying these specific mutations is essential because they can significantly impact how a cancer responds to certain therapies. This information allows oncologists to tailor treatment plans for better patient outcomes. This test analyzes the patient's tumor tissue to determine the presence of these mutations, helping to select the most effective treatment strategies. Discuss this test with your doctor if you have been diagnosed with certain types of cancer to understand if it's appropriate for you.

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

Speak with us

We check the test and answer your questions before collection.

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

Understand your report

A counselor helps you understand the result and the next steps.

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →

PreparationNo specific patient preparation is required. Ensure the FFPE tissue block is properly labeled and accompanied by a completed NGS Test Requisition Form (Form 40). Confirm with the laboratory before booking.

SampleA formalin-fixed paraffin-embedded (FFPE) tissue block containing at least 10% tumor tissue is required. The sample should be shipped at room temperature.

MethodologyThe test utilizes molecular techniques to analyze DNA extracted from the provided tissue sample, specifically looking for mutations in the KRAS and NRAS genes. Confirm with the laboratory before booking.

PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.

This test analyzes specific mutations in the KRAS and NRAS genes. It may not detect all possible mutations or other genetic alterations relevant to the cancer. Results should be interpreted in the context of the patient's overall clinical picture. Confirm with the laboratory before booking.

Read your report

What common result terms mean

TermPlain-language meaning

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.

NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.

VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.

Questions people ask

Frequently asked questions

KRAS and NRAS are genes that play a role in cell growth and division. Mutations in these genes can contribute to the development and progression of certain cancers.

The presence of specific KRAS or NRAS mutations can predict whether certain targeted cancer therapies will be effective. This test helps doctors choose the best treatment approach.

A formalin-fixed paraffin-embedded (FFPE) tissue block from a tumor biopsy or surgery is required. It should contain at least 10% tumor cells.

Results are typically available the following Monday if the sample is submitted by Tuesday at 11 am. Please confirm the current turnaround time with the laboratory.

We offer home sample collection services for your convenience. Please contact us to arrange this.

The current discount price is KSh 30,000. Please confirm the price with the laboratory before booking.

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

ACMG/AMP technical standards for sequence variant interpretation
ClinGen curation and gene–disease validity frameworks where applicable
LOINC-coded reporting for interoperable results
ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

Last updated: September 27, 2026
Medical review: not yet completed
Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Chat on WhatsApp